No Data
No Data
Huafu Securities: Significant differentiation in pharmaceutical interim reports, bullish on Pharma and innovative drugs.
Fundamentally, last week saw a high concentration of pharmaceutical mid-year reports, with some differentiation but overall industry pressure and bearish expectations materializing. Considering the upward year-on-year growth rate in the industry in Q3, along with the upcoming catalytic factors such as the implementation of innovative drug industry chain support policies and the start of medical insurance negotiations, the overall trend of the industry is upward.
CSPC Innovation Pharmaceutical's (SZSE:300765) Sluggish Earnings Might Be Just The Beginning Of Its Problems
CSPC Innovation Pharmaceutical: Half-year report for the year 2024.
CSPC Innovation Pharmaceutical: Summary of Half-Year Report in 2024.
Due to lower caffeine prices, CSPC Innovation Pharmaceutical's Q2 performance continued the downward trend from Q1. | Interpretations
Due to factors such as the decline in caffeine prices, CSPC Innovation Pharmaceutical's revenue and net income have both declined. Several pipelines in CSPC Innovation Pharmaceutical have made progress, and Enracuab monoclonal antibody has been conditionally approved for listing in June of this year. In order to enhance the industrialization capability of monoclonal antibody and ADCs, the company announced that CSPC Biotech will invest in the construction of two production line projects.
CSPC Innovation Pharmaceutical (300765.SZ): Jusheng Biotech plans to build a monoclonal antibody production line and ADC new product commercial production line, with a total investment of no more than 0.9 billion yuan.
CSPC Innovation Pharmaceutical (stock code 300765.SZ) announced that its subsidiary CSPC Pharma's Jusheng Bio-Pharmaceutical Co., Ltd. (referred to as ...
No Data
No Data